A landmark moment in our journey bringing together the world’s foremost oncology minds to accelerate the future of single-cell multi-omics and cell biopsy technology.
A Board Built for the Future of Oncology
At 1Cell.ai, we have always believed that the strength of our science is amplified by the strength of the people who believe in it. Today, we are thrilled to announce the establishment of our inaugural Clinical Advisory Board- an elite group of globally recognised Key Opinion Leaders in oncology, chaired by Nobel Laureate Dr. James Rothman, Sterling Professor of Cell Biology at Yale University’s School of Medicine and recipient of the 2013 Nobel Prize in Physiology or Medicine.
This board represents a defining moment in our mission to democratise precision oncology. With Dr. Rothman’s extraordinary leadership and the collective decades of clinical and research expertise our advisors bring, we are better positioned than ever to accelerate the global adoption of our breakthrough single-cell multi-omics and Cell Biopsy® technologies.
Meet Our Clinical Advisory Board
We are honoured to welcome the following distinguished oncology leaders to our board:
- Dr. Ravindra Kolhe: Associate Dean for Translational Research, Medical College of Georgia; Edgar R. Pund, MD Distinguished Chair of Pathology
- Dr. Funda Meric-Bernstam: Chair, Investigational Cancer Therapeutics, MD Anderson Cancer Center
- Dr. David Carbone: Director, James Thoracic Oncology Center, Ohio State University
- Dr. Razelle Kurzrock: Professor of Medicine, Medical College of Wisconsin
- Dr. Christian Rolfo: Director, Medical Oncology Division, Ohio State University Comprehensive Cancer Center
- Dr. Charles Cobbs: Director, Ivy Center for Advanced Brain Tumor Treatment, Swedish Hospital Allen Institute
What This Means for Our Mission
“We are privileged to welcome such esteemed leaders in oncology to this clinical advisory board,” said Mohan Uttarwar, CEO and Co-founder of 1Cell.ai. “With Dr. Rothman’s leadership and representation from globally notable organisations, we can leverage the collective expertise of this exceptional team and their decades of extensive research and clinical acumen. They will dramatically expand advocacy for our single-cell multi-omics approach, providing oncologists worldwide with unprecedented insights into cancer data that will transform treatment decisions on a global scale.”
“I am delighted to chair the advisory board, collaborating with other renowned KOLs in the field,” added Dr. James Rothman. “With any early-stage company, this kind of technology and progress needs validation, and our new advisory team will be able to provide just that.”
Introducing Cell Biopsy® – The Third Generation of Molecular Diagnostics
The formation of this advisory board comes at a pivotal moment in our scientific evolution. Our introduction of Cell Biopsy® as a distinct third generation of molecular diagnostics represents a fundamental leap beyond first-generation tissue biopsies and second-generation liquid biopsies. Unlike traditional liquid biopsies that analyse only circulating tumour DNA, our proprietary technology captures live Circulating Tumor Cells (CTCs) for comprehensive downstream multi-omics analysis-delivering 100 times more information through simultaneous DNA, RNA, and protein profiling from a single blood draw.
Precision Oncology Leadership Summit – Mumbai
As part of our commitment to advancing precision oncology with leading researchers and oncologists in India, we are also hosting our inaugural Precision Oncology Leadership Summit: “Pioneering Precision: Transforming Oncology Through Innovation” – at The Westin, Powai Lake, Mumbai on April 5-6. This landmark event, the first of its kind in India, will bring together more than 100 doctors, innovators, investors, and scientists shaping oncology’s future, with key speakers including Dr. Rothman and Dr. Pankaj Chaturvedi, Director of ACTREC.
Looking Ahead
With world-class advisors, an expanding global network of academic and research partnerships, and a technology platform that is redefining what precision oncology can deliver, we are more committed than ever to our mission- making precision oncology actionable, accessible, and affordable for every patient, everywhere.